Prescient Therapeutics Ltd has released a press release.
PTX-100 to Re-enter Trials in Hematology Niche
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
In the deck
Earlier from Prescient Therapeutics
- Prescient to resume AML trial
- Appendix 4E and 2017 Annual Report
- June 2017 Appendix 4C - Quarterly
- Novel PTX-100 Cancer Approach Published in Nature
- Clinical Trial Update
Later from Prescient Therapeutics
- September 2017 Appendix 4C - Quarterly
- PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer
- Clinical Hold Lifted on PTX-200 Breast Cancer Trial
- Clinical Trial Updates
- December 2017 Appendix 4C - Quarterly
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics